Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands

被引:12
作者
Brauns, O [1 ]
Brauns, S [1 ]
Zimmermann, B [1 ]
Jahn, O [1 ]
Spiess, J [1 ]
机构
[1] Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, D-37075 Gottingen, Germany
关键词
sauvagine; antisauvagine; CRF; urocortin II; urocortin-related peptide; CRF receptor;
D O I
10.1016/S0196-9781(02)00014-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The role of the N-terminal domains of corticotropin-releasing factor (CRF) and CRF-like peptides in receptor subtype selectivity, ligand affinity and biological potency was investigated. Therefore, human CRF12-41, human URP12-38 and antisauvagine-30 (aSvg) were N-terminally prolonged by consecutive addition of one or two amino acids. The peptides obtained were tested for their binding affinities to rat CRF1 and murine CRF2beta receptor, and their capability to stimulate cAMP-release by HEK cells producing either receptor. It was observed that human CRF N-terminally truncated by eight residues was bound with high affinity to CRF, receptor (K-i = 5.4 nM), whereas affinity for CRF1 receptor was decreased (Ki = 250 nM). A similar shift of affinity was found with sauvagine (Svg) analogs. Truncation of human URP analogs did not affect their preference for CRF2beta receptor, but reduced their affinity. Changes in affinity were positively correlated with changes in potency. These results indicated that CRF1 receptor was more stringent in its structural requirements for ligands to exhibit high affinity binding than CRF2beta receptor. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:881 / 888
页数:8
相关论文
共 36 条
[1]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[2]   A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor [J].
Beyermann, M ;
Fechner, K ;
Furkert, J ;
Krause, E ;
Bienert, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) :3324-3330
[3]   Pharmacological and chemical properties of astressin, antisauvagine-30 and α-helCRF:: significance for behavioral experiments [J].
Brauns, O ;
Liepold, T ;
Radulovic, J ;
Spiess, J .
NEUROPHARMACOLOGY, 2001, 41 (04) :507-516
[4]   Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions [J].
Cervini, L ;
Theobald, P ;
Corrigan, A ;
Craig, AG ;
Rivier, C ;
Vale, W ;
Rivier, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (04) :761-768
[5]   EXPRESSION CLONING OF A HUMAN CORTICOTROPIN-RELEASING-FACTOR RECEPTOR [J].
CHEN, RP ;
LEWIS, KA ;
PERRIN, MH ;
VALE, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8967-8971
[6]  
Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640
[7]   Molecular biology of the CRH receptors - in the mood [J].
Dautzenberg, FM ;
Kilpatrick, GJ ;
Hauger, RL ;
Moreau, JL .
PEPTIDES, 2001, 22 (05) :753-760
[8]   Corticotropin-releasing factor receptors: An overview [J].
Dieterich, KD ;
Lehnert, H ;
DeSouza, EB .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1997, 105 (02) :65-82
[9]   Cloning and characterization of human urocortin [J].
Donaldson, CJ ;
Sutton, SW ;
Perrin, MH ;
Corrigan, AZ ;
Lewis, KA ;
Rivier, JE ;
Vaughan, JM ;
Vale, WW .
ENDOCRINOLOGY, 1996, 137 (05) :2167-2170
[10]  
Eckart K, 1999, CURR MED CHEM, V6, P1035